Shots: The acquisition is focus on development of vaccines for adenovirus types 4 and 7, and expanding the company’s vaccine product portfolio Emergent to pay an upfront ~$270M in cash to get hold of PaxVax’s two marketed vaccines- Vivotif and Vaxchora and pipeline products Vivotif (Typhoid Vaccine Live Oral Ty21a), and Vaxchora (Cholera Vaccine, Live, […]Read More
Tags : PaxVax
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US